REmote SUpervision to Decrease HospitaLization RaTe. Unified and integrated platform for data collected from devices manufactured by different companies: Design and rationale of the RESULT study
Mateusz Tajstra, Adam Sokal, Arkadiusz Gwóźdź, Marcin Wilczek, Adam Gacek, Konrad Wojciechowski, Elżbieta Gadula-Gacek, Elżbieta Adamowicz-Czoch, Katarzyna Chłosta-Niepiekło, Krzysztof Milewski, Piotr Rozentryt, Zbigniew Kalarus, Mariusz Gąsior, Lech Poloński, Mateusz Tajstra, Adam Sokal, Arkadiusz Gwóźdź, Marcin Wilczek, Adam Gacek, Konrad Wojciechowski, Elżbieta Gadula-Gacek, Elżbieta Adamowicz-Czoch, Katarzyna Chłosta-Niepiekło, Krzysztof Milewski, Piotr Rozentryt, Zbigniew Kalarus, Mariusz Gąsior, Lech Poloński
Abstract
The number of patients with heart failure implantable cardiac electronic devices (CIEDs) is growing. Hospitalization rate in this group is very high and generates enormous costs. To avoid the need for hospital treatment, optimized monitoring and follow-up is crucial. Remote monitoring (RM) has been widely put into practice in the management of CIEDs but it may be difficult due to the presence of differences in systems provided by device manufacturers and loss of gathered data in case of device reimplantation. Additionally, conclusions derived from studies about usefulness of RM in clinical practice apply to devices coming only from a single company. An integrated monitoring platform allows for more comprehensive data analysis and interpretation. Therefore, the primary objective of Remote Supervision to Decrease Hospitalization Rate (RESULT) study is to evaluate the impact of RM on the clinical status of patients with ICDs or CRT-Ds using an integrated platform. Six hundred consecutive patients with ICDs or CRT-Ds implanted will be prospectively randomized to either a traditional or RM-based follow-up model. The primary clinical endpoint will be a composite of all-cause mortality or hospitalization for cardiovascular reasons within 12 months after randomization. The primary technical endpoint will be to construct and evaluate a unified and integrated platform for the data collected from RM devices manufactured by different companies. This manuscript describes the design and methodology of the prospective, randomized trial designed to determine whether remote monitoring using an integrated platform for different companies is safe, feasible, and efficacious (ClinicalTrials.gov Identifier: NCT02409225).
Keywords: RESULT study; heart failure; integrated platform; remote monitoring.
Conflict of interest statement
None declared.
© 2016 Wiley Periodicals, Inc.
Figures



Source: PubMed
Предстоящие клинические испытания
-
University of TennesseeWoodcock Institute for the Advancement of Neurocognitive Research and Applied PracticeЕще не набираютДвигательные навыки | Здоровый | Исполнительная функция
-
University of Texas Southwestern Medical CenterMerck Sharp & Dohme LLCЕще не набираютАнальная плоскоклеточная карцинома
-
Universita di VeronaAzienda Ospedaliera Universitaria Integrata VeronaЕще не набираютРевматоидный артрит | Дегенеративное заболевание коленного суставаИталия
-
University of Wisconsin, MadisonAlkermes, Inc.Еще не набирают
-
Virginia Commonwealth UniversityЕще не набираютОтек мозга | Радиационный некрозСоединенные Штаты
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH); Icahn School of Medicine at Mount SinaiЕще не набираютКетамин | фМРТ | Депрессия - Большое депрессивное расстройство | рТМС | Резистентная к лечению депрессия (TRD)Соединенные Штаты
-
Weill Medical College of Cornell UniversityBD2 LLCЕще не набираютфМРТ | Биполярное расстройство (БД) | рТМС | Биполярная депрессия 1Соединенные Штаты
-
Xentria, Inc.Еще не набирают
-
Yale UniversityNational Institute of Mental Health (NIMH)Еще не набирают
-
Cambridge University Hospitals NHS Foundation TrustUniversity of CambridgeРекрутингФеохромоцитома | Феохромоцитома/параганглиома | Феохромоцитома, Метастатическая | Феохромоцитома злокачественная | Феохромоцитома и параганглиома (PPGL)Соединенное Королевство
-
Carl Zeiss Meditec-Dublin CoCeРекрутингЭпиретинальная мембрана | Болезнь сетчатки | Дегенерация желтого пятна, связанная с сухим возрастом | Витреоретинальная аномалия | Macular Abnormalities | Intraretinal Hyporeflective Space | Subretinal Hyporeflective Space | IS/OS (Ellipsoid Zone) Disruption | Retinal Pigment Epithelium (RPE) Elevation и другие заболеванияСоединенные Штаты
-
Celest Therapeutics (Shanghai) Co., Ltd.The First Affiliated Hospital of Anhui Medical UniversityРекрутингCLDN18.2 Положительные солидные опухолиКитай